<DOC>
	<DOCNO>NCT00826878</DOCNO>
	<brief_summary>This standard Phase 1b 2a , multi-center , study design examine safety , tolerability , maximum tolerate dose tivozanib ( AV-951 ) dose schedule , well overall response rate tivozanib ( AV-951 ) administration NSCLC .</brief_summary>
	<brief_title>An Open-Label Study QD Oral Administration Tivozanib ( AV-951 ) Subjects With Non-Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description>The Phase 2a portion study conduct</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>1 . Age 18 year old , either sex race . 2 . Histologically cytologically confirm NSCL . 3 . Stage IIIB ( malignant pleural effusion ) stage IV recurrent disease . 4 . Subjects recur progress follow standard therapy fail standard therapy ; subject candidate unwilling undergo standard therapy . 5 . Disease currently amenable curative surgical intervention , due either nonresectability tumor medical contraindication . 6 . Prior VEGF direct therapy 7 . Prior chemotherapy 8 . At least 4 week since prior immunotherapy ( eg , IL2 , IFN , etc . ) biological therapy ( eg , MABs ) prior first dose study drug . 9 . At least 1 week since prior treatment warfarin , acenocoumarol , fenprocoumon , similar agent . 10 . At least 4 week since prior systemic hormonal therapy . 11 . At least 2 week since prior use herbal preparations/supplements . 12 . At least 2 week since prior treatment CYP3A4 inducer inhibitor . 13 . At least 2 week since prior radiotherapy ≤25 % bone marrow , least 4 week since prior radiotherapy &gt; 25 % bone marrow . 14 . Measurable evaluable disease ; subject enrol Phase 2a study must measurable disease RECIST criterion . 15 . ECOG performance 01 life expectancy ≥ 3 month . 16 . Ability give write informed consent . 1 . Subjects central lung lesion involve major blood vessel . 2 . Primary CNS malignancy symptomatic CNS metastasis ; subject previously treat brain metastasis allow brain metastasis stable without steroid treatment least 3 month follow prior treatment ( radiotherapy surgery ) . 3 . Hematologic malignancy ( include leukemia form , lymphoma , multiple myeloma ) . 4 . Hematologic abnormality : 5 . Serum chemistry abnormality : 6 . Significant cardiovascular disease 7 . Subjects delay heal wound , active gastric ulcer , unhealed bone fracture . 8 . Serious/active infection infection require parenteral antibiotic . 9 . Inadequate recovery prior surgical procedure major surgical procedure within 6 week prior administration first dose study drug . 10 . Inability comply protocol requirement . 11 . History ≥ Grade 2 hemoptysis within 6 month prior administration first dose study drug ; ongoing bleeding ( hemoptysis , hematemesis , hematochezia melena ) history clinically significant bleeding within 6 month prior administration first dose study drug . 12 . Cerebrovascular accident within 12 month prior administration first dose study drug , peripheral vascular disease claudication walk less 1 block . 13 . Deep venous thrombosis pulmonary embolus within 6 month prior administration first dose study drug . 14 . Subjects `` currently active '' second primary malignancy nonmelanoma skin cancer nonmetastatic prostate cancer . Subjects consider `` currently active '' malignancy complete anticancer therapy disease free &gt; 2 year . 15 . If female , pregnant lactating . 16 . No childbearing potential use effective contraception fertile male female subject study 30 day last dose study drug . All subject must agree use highly effective method contraception ( include partner ) . 17 . Known concomitant genetic acquire immune suppression disease HIV . 18 . Inadequate recovery prior antineoplastic therapy . 19 . Lifethreatening illness organ system dysfunction compromise safety evaluation . 20 . Psychiatric disorder , alter mental status precluding inform consent necessary testing .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>tivozanib</keyword>
	<keyword>AV-951</keyword>
</DOC>